BCTX
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.
BriaCell Therapeutics Corp. (BCTX) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (C+); its weakest is Profitability (D). The rating has held at C for 15 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-17 | C+ (2.5) | C+ (2.5) | D (1.2) | C+ (2.7) | C+ (2.6) | C (2.3) |
| 2026-11-10 | C+ (2.5) | C+ (2.5) | D (1.2) | C+ (2.7) | C+ (2.6) | C (2.3) |
| 2026-11-03 | C+ (2.5) | C+ (2.5) | D (1.3) | C+ (2.6) | C+ (2.7) | C (2.3) |
| 2026-10-27 | C+ (2.5) | C+ (2.5) | D (1.4) | C+ (2.6) | C+ (2.6) | C (2.3) |
| 2026-10-20 | C+ (2.5) | C+ (2.5) | D (1.4) | C (2.4) | C+ (2.6) | C (2.3) |